Background
Local anaesthesia is a common requirement for the performance of most dental procedures. The market offers many types of anaesthetics, but the greatest difference between them is the addition of vasoconstrictor agents. Some authors state that plain anaesthetics do not provide sufficient anaesthesia [1] [2] [3] . Vasoconstrictor agents have many advantages, such as delaying the absorption of local anaesthetics, increasing patient welfare due to the lower doses of anaesthetic required, diminishing potential toxic risk, and providing bleeding control [4] . Despite these benefits, its use has been limited due to fear of systemic absorption and the induction of adverse effects in cardiac compromised patients; it has sometimes been controversial [5] . However pain, stress, and fear are also responsible for the systemic liberation of endogenous catecholamines that can cause an autonomic response, such as provoking acute arrhythmias [6] . It should be noted that epinephrine released endogenously is a higher dose than that used in dental anaesthesia [7] [8] [9] .
According to American Heart Association (AHA) and American Dental Association (ADA) guidelines, there is no contraindication to using a vasoconstrictor agent when administrated carefully and with preliminary aspiration [10] . The maximum dose of epinephrine in local anaesthesia for a healthy subject is 0.2 mg, though this can be lowered to 0.04 mg if patient has severe cardiovascular disease (ASA III and IV) [11] . Therefore, the aim of this study was to review the literature to assess any scientific basis for the limited use of dental anaesthesia with a vasoconstrictor agent in cardiovascular compromised patients.
Material and Methods
On June 13 th , 2013, a comprehensive database search was executed with the use of Medline (PubMed), ISI Web of Science, and Cochrane. No language frame was used. Only publications from the last 15 years were considered.
Search equations are presented in Table 1 . To correctly translate the equation for other databases, the help of a senior librarian was obtained. The titles and abstracts that were found with an electronic search were screened and evaluated by 2 observers according to inclusion and exclusion criteria ( Table 2 ). Studies that did not meet the defined criteria were excluded from further evaluation. Any discrepancies in the selection were settled through discussion. A prisma flow diagram illustrates the search and evaluation process ( Figure 1 ).
To provide reliable evidence, a critical appraisal of all included articles was carried out. The criteria for this purpose were applied from the "Methods Guide for Comparative Effectiveness Reviews" created by the American Agency for Healthcare Research and Quality [12] . The overall judgement was assessed as high or unclear risk, when 1 or more key domains was assessed as high or unclear. A low-risk judgement was formed when all key domains were at "low risk". This review was registered in "PROSPERO International prospective register of systematic reviews" as CRD42013004928.
Results
Of the 294 articles initially found, an automatic rejection of duplicates in the EndNote X5 reference manager resulted in 138 articles. After screening the abstracts, 100 articles were excluded. Eligibility verification of full-text articles resulted in the final inclusion of 11 papers.
Six randomized clinical trials (RCT) and 5 controlled clinical trials (CCT) with no randomization met the inclusion criteria across all studies.
The risk of bias assessment revealed that all RCTs were low risk. Among CCTs, 2 papers had unclear risk and 3 had low risk.
More detailed information is presented in Table 3 .
The total number of patients was 567. Seven patients were excluded, 1 due to missing documentation (Elad et al.) and 6 due to motion artefacts during ECG (Neves et al.) . Demographic data are presented in Table 4 .
Among all of the included patients, the most frequent underlying pathology was hypertension. Other conditions are presented in Figure 2 . When 1 patient was related to 2 or more categories, it was assigned to each relevant group. 
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Among 560 patients after the administration of a local anaesthetic, 87 complications occurred. The most frequent complication was arrhythmia. Asymptomatic ischaemic changes were seen in 3 patients. One case of transient local neuropathy was noted (Table 5) . No severe adverse clinical effects were reported.
Discussion
A mean age of over 50, being male, and the presence of comorbid disease may provide a representative group. Other increased levels of evidence and low risk of bias in the included articles could be sufficient evidence for clinical decisions to be made.
The overall complication rate across studies was 15.5%. The highest proportion of complication (43.6%) was reported by Middlehurst et al. with noradrenaline (1:50000) + vasopressin 0.25 IU/ml. Additionally, midazolam was administrated as a premedication in 1 of the study groups. This high complication rate could result from the monitoring method used. Middlehurst et al. counted and analysed ECG waves (QRS complexes) from the sedation to recovery period. However, 2.7% of waves from LNEV and 5.7% from the LNEV+M group were found to be clinically significant [15] . It should also be noted that the anaesthesia scheme presented by Middlehurst et al. is not the most commonly used method in dental practice. Excluding this study from analysis due to inability to define the number of patients with clinically significant complications, the overall complication rate decreases to 8.75%. 
Conclusions
1. The most frequent complications in cardiovascular compromised patients after dental local anaesthesia with vasoconstrictor agent were disclosed in ECG arrhythmias. 2. The range of diagnostic criteria complication frequency depends on application by different authors and ranges from 0% to 50%. 3. A major part of the disclosed arrhythmias were clinically insignificant. 4. The use of ≤4 ampules of lignocaine with epinephrine 1:100000 as a dental anaesthetic seems to be relatively safe for cardiovascular compromised patients. 5. During the application of higher doses of anaesthesia or a higher concentration of an anaesthetic agent in cardiovascular compromised patients, ECG monitoring should be considered due to insufficient evidence of the safety of higher dosage use.
